When a DHP calcium channel blocker is added to a regimen for poorly controlled hypertension, which adverse event should be monitored?

When a dihydropyridine (DHP) calcium channel blocker is incorporated into the treatment plan for poorly controlled hypertension, one of the primary adverse events to monitor for is peripheral edema. DHP calcium channel blockers work by causing vasodilation, which can lead to increased pressure in the capillaries and subsequent leakage of fluid into surrounding tissues. This mechanism can result in significant swelling, particularly in the lower extremities, known as peripheral edema.

It's important to monitor for this side effect, as it can affect the patient’s comfort and adherence to the medication regimen. The management of peripheral edema may require dosage adjustments or the addition of diuretics for some patients, making awareness and assessment crucial.

Other adverse events listed, while relevant in some contexts, do not have the same direct association with DHP calcium channel blockers. Hypernatremia is not typically a concern with these agents, nor is hypoglycemia, which is usually linked to other classes of medications such as insulin or oral hypoglycemics. Flushing is more commonly associated with non-dihydropyridine calcium channel blockers rather than DHPs. Therefore, the focus on peripheral edema is particularly pertinent when evaluating the effects of DHP calcium channel blockers in hypertension management.